Expression of gastrin-releasing peptide receptor in patients with cutaneous malignant melanoma

Clinical and Experimental Dermatology

Volumn 38, Issue 7, 2013, Pages 707-712

  Marrone, B F ^a   Meurer, L ^a   Moretto, A ^a   Kleina, W ^a   Schwartsmann, G ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN RELEASING PEPTIDE RECEPTOR;

ARTICLE; CANCER PROGNOSIS; CUTANEOUS MELANOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY; TUMOR BIOPSY;

HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEOPLASM PROTEINS; PROGNOSIS; RECEPTORS, BOMBESIN; SKIN NEOPLASMS;

EID: 84884910373     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12058     Document Type: Article

References (25)

1. Geller AC, Muler DR, Annas GD, et al,. Melanoma incidence and mortality among US whites,1969-99. JAMA 2002; 288: 1719-20.
2. Hill G, Krementz E, Hill H,. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. Cancer 1984; 53: 1299-305.
3. Rofstad EK, Halsør EF,. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 2000; 60: 4932-8.
4. Flaherty KT, Puzanov I, Kim KB, et al,. Inibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 36: 809-19.
5. Hodi FS, O'Day SJ, McDermott DF, et al,. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
6. Cornelio DB, Roesler R, Schwartsmann G,. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol 2007; 18: 1457-66.
7. Flores DG, Meurer L, Uberti AF, et al,. Gastrin-releasing peptide receptor content in human glioma and normal brain. Brain Res Bull 2010; 82: 95-8.
8. Benya RV,. Glycosilation of the gastrin-releasing peptide receptor and its effect on expression, G protein coupling, and receptor modulaty process. Mol Pharmacol 2000; 58: 1490-501.
9. Bajo AM, Schally AV, Groot K, Szepeshazi K,. Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers. Br J Cancer 2004; 90: 245-52.
10. Szepeshazi K, Schally AV, Halmos G, et al,. A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers. Proc Natl Acad Sci USA 1997; 94: 10913-18.
11. Schwartsmann G, DiLeone LP, Horowitz M, et al,. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest New Drugs 2006; 24: 403-12.
12. Scott N, Millward G, Cartwright EJ, et al,. Gastrin releasing peptide and gastrin releasing peptide receptor expression in gastrointestinal carcinoid tumors. J Clin Pathol 2004; 57: 189-92.
13. Anastasi A, Erspamer V, Bucci M,. Isolation and structure of bombesin and alytesin, two analogous active peptides from the skin of the European amphibians Bombina and Alityes. Experimentia 1971; 27: 16-17.
14. Sunday ME, Kaplan LM, Motoyama E, et al,. Biology of disease: gastrin-releasing peptide (mammalian bombesin) gene expression in health and disease. Lab Invest 1988; 59: 5-24.
15. Mason CS, Springer CJ, Cooper RG, et al,. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J 1999; 18: 2137-48.
16. Logothetis C, Hoosein N,. The inhibition of the paracrine progression of prostate cancer as an approach to early therapy of prostatic carcinoma. J Cell Biochem Suppl 1992; 16H: 128-34.
17. Bartholdi MF, Wu JM, Pu H, et al,. In situ hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma. Int J Cancer 1998; 79: 82-90.
18. Cuttitta F, Carney DN, Mulshine J, et al,. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985; 316: 823-6.
19. Gugger M, Reubi JC,. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol 1999; 155: 2067-76.
20. Halmos G, Wittliff JL, Schally AV,. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res 1995; 55: 280-7.
21. Carroll RE, Matkowskyj KA, Chakrabarti S, et al,. Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans. Am J Physiol 1999; 276: G655-65.
22. Uchida K, Kojima A, Morokawa N, et al,. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer. J Cancer Res Clin Oncol 2002; 128: 633-40.
23. Carroll RE, Carroll R, Benya RV,. Characterization of gastrin-releasing peptide receptors aberrantly expressed by non-antral gastric adenocarcinomas. Peptides 1999; 20: 229-37.
24. Lango MN, Dyer KF, Lui VW, et al,. Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. J Natl Cancer Inst 2002; 9: 375-83.
25. Charitopoulos K, Lazaris A, Aroni K, et al,. Immunodetection of gastrin-releasing peptide in malignant melanoma cells. Melanoma Res 2000; 10: 395-400.